Nano-optogenetic immunotherapy.
Nano-optogenetic immunotherapy.
复制标题
DOI：
10.1002/ctm2.1020
复制
发表时间：
2022-09
影响因子：
10.6
通讯作者：
Zhou, Yubin
中科院分区：
文献类型：
--
作者：
Huang, Kai;Liu, Xiaoxuan;Han, Gang;Zhou, Yubin
过去 5 年，基于嵌合抗原受体 (CAR) T 细胞的免疫疗法越来越多地应用于临床癌症干预。 CAR T 细胞疗法利用基因修饰的 T 细胞在细胞表面表达合成的 CAR 分子。迄今为止，已有多达六种CAR T细胞治疗产品获得美国食品药品监督管理局批准用于治疗白血病、淋巴瘤和多发性骨髓瘤。此外，数百种CAR-T产品目前正在进行治疗实体瘤的临床试验。无论是基础研究还是临床应用，CAR T细胞免疫疗法都取得了令人兴奋的进展，显着缓解或抑制了癌症。然而，基于 CAR T 细胞的免疫疗法仍然面临重大的安全问题，例如由于缺乏严格的抗原特异性而导致的“非肿瘤”细胞毒性。此外，输注的 CAR T 细胞不受控制的大量激活可能会产生严重的全身炎症，并伴有细胞因子释放综合征和神经毒性。这些挑战需要将纳米技术、光遗传学与免疫工程相结合，开发时空可控的 CAR T 细胞，从而实现治疗性免疫细胞的无线光可调激活，从而在肿瘤微环境中提供个性化治疗。
Chimeric antigen receptor (CAR) T cell‐based immunotherapy has been increasingly used in the clinic for cancer intervention over the past 5 years. CAR T‐cell therapy takes advantage of genetically‐modified T cells to express synthetic CAR molecules on the cell surface. To date, up to six CAR T cell therapy products have been approved by the Food and Drug Administration for the treatment of leukaemia, lymphoma, and multiple myeloma. In addition, hundreds of CAR‐T products are currently under clinical trials to treat solid tumours. In both the fundamental research and clinical applications, CAR T cell immunotherapy has achieved exciting progress with remarkable remission or suppression of cancers. However, CAR T cell‐based immunotherapy still faces significant safety issues, as exemplified by “on‐target off‐tumour” cytotoxicity due to lack of strict antigen specificity. In addition, uncontrolled massive activation of infused CAR T cells may create severe systemic inflammation with cytokine release syndrome and neurotoxicity. These challenges call for a need to combine nanotechnology and optogenetics with immunoengineering to develop spatiotemporally‐controllable CAR T cells, which enable wireless photo‐tunable activation of therapeutic immune cells to deliver personalised therapy in the tumour microenvironment.
登录
查看更多内容
影响因子：
28.1
作者：
通讯作者：
--
影响因子：
14.8
作者：
He, Lian;Tan, Peng;Zhou, Yubin
通讯作者：
Zhou, Yubin
影响因子：
22.7
作者：
Milone MC;Xu J;Chen SJ;Collins MA;Zhou J;Powell DJ Jr;Melenhorst JJ
通讯作者：
Melenhorst JJ
影响因子：
38.3
作者：
Nguyen NT;Huang K;Zeng H;Jing J;Wang R;Fang S;Chen J;Liu X;Huang Z;You MJ;Rao A;Huang Y;Han G;Zhou Y
通讯作者：
Zhou Y
影响因子：
64.5
作者：
Lim WA;June CH
通讯作者：
June CH